Arch Pharmalabs is an API manufacturer based in India. It holds 12 active US drug master files across a filed portfolio of 14 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 12 September 2025 as VAI. Customs aggregates show $17K of exports covering 6 molecules to 2 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Sangareddy District, India | 3007556480 |
| Thane, India | 3002808114 |
| Molecule | Regulators | Docs |
|---|---|---|
| Gemcitabine | US FDA | 2 |
| Meloxicam | SFDA (Saudi Arabia), US FDA | 2 |
| Piroxicam | SFDA (Saudi Arabia), US FDA | 2 |
| Amlodipine | US FDA | 1 |
| Atorvastatin | US FDA | 1 |
| Benzatropine | US FDA | 1 |
| Citalopram | US FDA | 1 |
| Clopidogrel | US FDA | 1 |
| Diclofenac | SFDA (Saudi Arabia) | 1 |
| Dicofenac | SFDA (Saudi Arabia) | 1 |
| Docetaxel | SFDA (Saudi Arabia) | 1 |
| Escitalopram | US FDA | 1 |
| Irinotecan | US FDA | 1 |
| Ursodeoxycholic Acid | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2025 | Not reported | $17K | 2 |
| 2024 | Not reported | $680K | 11 |
| 2023 | Not reported | $2.7M | 27 |
| 2022 | Not reported | $1.3M | 21 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Arch Pharmalabs comes back tiered against every other supplier able to file there.
Start for free